|
1
|
Hassanipour-Azgomi S,
Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S and
Salehiniya H: Incidence and mortality of prostate cancer and their
relationship with the Human Development Index worldwide. Prostate
Int. 4:118–124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Afriansyah A, Hamid ARAH, Mochtar CA and
Umbas R: Prostate specific antigen (PSA) kinetic as a prognostic
factor in metastatic prostate cancer receiving androgen deprivation
therapy: Systematic review and meta-analysis. F1000Res. 7:2462018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rawla P: Epidemiology of prostate cancer.
World J Oncol. 10:63–89. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taitt HE: Global Trends and Prostate
cancer: A review of incidence, detection, and mortality as
influenced by race, ethnicity, and geographic location. Am J Men's
Health. 12:1807–1823. 2018. View Article : Google Scholar
|
|
5
|
Adhyam M and Gupta AK: A review on the
clinical utility of PSA in cancer prostate. Indian J Surg Oncol.
3:120–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mundell NL, Daly RM, Macpherson H and
Fraser SF: Cognitive decline in prostate cancer patients undergoing
ADT: A potential role for exercise training. Endocr Relat Cancer.
24:R145–R155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McHugh DJ, Root JC, Nelson CJ and Morris
MJ: Androgen-deprivation therapy, dementia, and cognitive
dysfunction in men with prostate cancer: How much smoke and how
much fire? Cancer. 124:1326–1334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maughan BL, Antonarakis ES and Hopkins
Sidney Kimmel J: Androgen pathway resistance in prostate cancer and
therapeutic implications HHS Public Access. Expert Opin
Pharmacother. 16:1521–1537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hotte SJ and Saad F: Current management of
castrate-resistant prostate cancer. Curr Oncol. 17 (Suppl
2):S72–S79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nader R, El Amm J and Aragon-Ching JB:
Role of chemotherapy in prostate cancer. Asian J Androl.
20:221–229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sichero L and Villa LL: Epidemiological
and functional implications of molecular variants of human
papillomavirus. Brazilian J Med Biol Res. 39:707–717. 2006.
View Article : Google Scholar
|
|
12
|
Handy CE and Antonarakis ES: Sequencing
treatment for castration-resistant prostate cancer. Curr Treat
Options Oncol. 17:642016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vanagas G, Mickevičienė A and Ulys A: Does
quality of life of prostate cancer patients differ by stage and
treatment? Scand J Public Health. 41:58–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farris MS, Kopciuk KA, Courneya KS,
McGregor SE, Wang Q and Friedenreich CM: Identification and
prediction of health-related quality of life trajectories after a
prostate cancer diagnosis. Int J Cancer. 140:1517–1527. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Charalambous A and Kouta C: Cancer related
fatigue and quality of life in patients with advanced prostate
cancer undergoing chemotherapy. Biomed Res Int. 2016:39892862016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dun YJ, Liu HX, Yu LP, Li Q, Zhang XW,
Tang X, Qin CP and Xu T: Development and initial validation of the
novel scale for assessing quality of life of prostate cancer
patients receiving androgen deprivation therapy. Chin Med J (Engl).
130:2082–2087. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chambers SK, Ng SK, Baade P, Aitken JF,
Hyde MK, Wittert G, Frydenberg M and Dunn J: Trajectories of
quality of life, life satisfaction, and psychological adjustment
after prostate cancer. Psychooncology. 26:1576–1585. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jang JW, Drumm MR, Efstathiou JA, Paly JJ,
Niemierko A, Ancukiewicz M, Talcott JA, Clark JA and Zietman AL:
Long-term quality of life after definitive treatment for prostate
cancer: Patient-reported outcomes in the second posttreatment
decade. Cancer Med. 6:1827–1836. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Griffin K, Csizmadi I, Howard LE, Pomann
GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK,
Beebe-Dimmer J and Freedland SJ: First-year weight loss with
androgen-deprivation therapy increases risks of prostate cancer
progression and prostate cancer-specific mortality: Results from
SEARCH. Cancer Causes Control. 30:259–269. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Valente SM: End-of-life challenges:
Honoring autonomy. Cancer Nurs. 27:314–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Attard G, Borre M, Gurney H, Loriot Y,
Andresen-Daniil C, Kalleda R, Pham T and Taplin ME; PLATO
collaborators, : Abiraterone alone or in combination with
enzalutamide in metastatic castration-resistant prostate cancer
with rising prostate-specific antigen during enzalutamide
treatment. J Clin Oncol. 36:2639–2646. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haberkorn U, Eder M, Kopka K, Babich JW
and Eisenhut M: New strategies in prostate cancer:
Prostate-specific membrane antigen (PSMA) ligands for diagnosis and
therapy. Clin Cancer Res. 22:9–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sumanasuriya S and De Bono J: Treatment of
advanced prostate cancer-a review of current therapies and future
promise. Cold Spring Harb Perspect Med. 8:a0306352018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yiannakopoulou E: Targeting epigenetic
mechanisms and microRNAs by aspirin and other non steroidal
anti-inflammatory agents-Implications for cancer treatment and
chemoprevention. Cell Oncol (Dordr). 37:167–178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma Y and Brusselaers N: Maintenance use of
aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and
prostate cancer risk. Prostate Cancer Prostatic Dis. 21:147–152.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Algotar AM, Behnejad R, Stratton MS and
Stratton SP: Chronic use of NSAIDs and/or statins does not affect
PSA or PSA velocity in men at high risk for prostate cancer. Cancer
Epidemiol Biomarkers Prev. 23:2196–2198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Manley G: Aspirin, NSAID and risk of
prostate cancer: Results from the REDUCE study. Clin Cancer Res.
71:233–236. 2013.
|
|
28
|
Solheim TS, Fearon KC, Blum D and Kaasa S:
Non-steroidal anti-inflammatory treatment in cancer cachexia: A
systematic literature review. Acta Oncol. 52:6–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Veitonmäki T, Murtola TJ, Talala K, Taari
K, Tammela T and Auvinen A: Non-steroidal anti-inflammatory drugs
and cancer death in the finnish prostate cancer screening trial.
PLoS One. 11:e01534132016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Flamiatos JF, Beer TM, Graff JN, Eilers
KM, Tian W, Sekhon HS and Garzotto M: Cyclooxygenase-2 (COX-2)
inhibition for prostate cancer chemoprevention: double-blind
randomised study of pre-prostatectomy celecoxib or placebo. BJU
Int. 119:709–716. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Soriano-Hernández AD, Galvan-Salazar HR,
Montes-Galindo DA, Rodriguez-Hernandez A, Martinez-Martinez R,
Guzman-Esquivel J, Valdez-Velazquez LL, Baltazar-Rodriguez LM,
Espinoza-Gómez F, Rojas-Martinez A, et al: Antitumor effect of
meclofenamic acid on human androgen-independent prostate cancer: A
preclinical evaluation. Int Urol Nephrol. 44:471–477. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bonn SE, Wiklund F, Sjölander A, Szulkin
R, Stattin P, Holmberg E, Grönberg H and Bälter K: Body mass index
and weight change in men with prostate cancer: Progression and
mortality. Cancer Causes Control. 25:933–943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jackson SE, Heinrich M, Beeken RJ and
Wardle J: Weight loss and mortality in overweight and obese cancer
survivors: A systematic review. PLoS One. 12:1–21. 2017. View Article : Google Scholar
|
|
34
|
Pandis N, Chung B, Scherer RW, Elbourne D
and Altman DG: CONSORT 2010 statement: Extension checklist for
reporting within person randomised trials. BMJ. 357:j28352017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scher HI, Morris MJ, Stadler WM, Higano C,
Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, et
al: Trial design and objectives for castration-resistant prostate
cancer: Updated recommendations from the prostate cancer clinical
trials working Group 3. J Clin Oncol. 34:1402–1418. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hernandez DJ, Nielsen ME, Han M and Partin
AW: Contemporary evaluation of the D'amico risk classification of
prostate cancer. Urology. 70:931–935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kok B and Abraldes J: Child-pugh
classification: Time to abandon? Semin Liver Dis. 39:96–103. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Singer M, Deutschman CS, Seymour CW,
Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche
JD, Coopersmith CM, et al: The third international consensus
definitions for sepsis and septic shock (Sepsis-3). Jama.
315:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dueck AC, Mendoza TR, Mitchell SA, Reeve
BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM,
O'Mara AM, et al: Validity and reliability of the US national
cancer institute's patient-reported outcomes version of the common
terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol.
1:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lutz S, Berk L, Chang E, Chow E, Hahn C,
Hoskin P, Howell D, Konski A, Kachnic L, Lo S, et al: Palliative
radiotherapy for bone metastases: An ASTRO evidence-based
guideline. Int J Radiat Oncol Biol Phys. 79:965–976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Blanchard CM, Stein K and Courneya KS:
Body mass index, physical activity, and health-related quality of
life in cancer survivors. Med Sci Sports Exerc. 42:665–671. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hernandez G, Garin O, Pardo Y, Vilagut G,
Pont À, Suárez M, Neira M, Rajmil L, Gorostiza I, Ramallo-Fariña Y,
et al: Validity of the EQ-5D-5L and reference norms for the Spanish
population. Qual Life Res. 27:2337–2348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao J, Shen P, Sun G, Chen N, Liu J, Tang
X, Huang R, Cai D, Gong J, Zhang X, et al: The prognostic
implication of intraductal carcinoma of the prostate in metastatic
castration-resistant prostate cancer and its potential predictive
value in those treated with docetaxel or abiraterone as first-line
therapy. Oncotarget. 8:55374–83. 2017.PubMed/NCBI
|
|
45
|
Greenland S: Small-sample bias and
corrections for conditional maximum-likelihood odds-ratio
estimators. Biostatistics. 1:113–122. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
de Bono JS, Logothetis CJ, Molina A,
Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F,
et al: Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chang LW, Hung SC, Wang SS, Li JR, Yang
CK, Chen CS, Ho HC, Cheng CL and Ou YC CK: Abiraterone acetate and
enzalutamide: Similar efficacy in treating post docetaxel
metastatic castration-resistant prostate cancer: Single center
experience. Anticancer Res. 39:3901–3908. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yamashita S, Kohjimoto Y, Iguchi T, Koike
H, Kusumoto H, Iba A, Kikkawa K, Kodama Y, Matsumura N and Hara I:
Prognostic factors and risk stratification in patients with
castration-resistant prostate cancer receiving docetaxel-based
chemotherapy. BMC Urol. 16:132016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Harirforoosh S, Asghar W and Jamali F:
Adverse effects of nonsteroidal antiinflammatory drugs: An update
of gastrointestinal, cardiovascular and renal complications. J
Pharm Pharm Sci. 16:821–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mimeault M, Johansson SL, Henichart JP,
Depreux P and Batra SK: Cytotoxic effects induced by docetaxel,
gefitinib, and cyclopamine on side population and nonside
population cell fractions from human invasive prostate cancer
cells. Mol Cancer Ther. 9:617–630. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Baker J, Ajani J, Scotté F, Winther D,
Martin M, Aapro MS and von Minckwitz G: Docetaxel-related side
effects and their management. Eur J Oncol Nurs. 13:49–59. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Climent MÁ, Torregrosa MD, Vázquez S,
Gironés R and Arranz JA: Aged patients with metastatic castration
resistant prostate cancer: Should we treat with chemotherapy?
Cancer Treat Rev. 55:173–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Benidir T, Hersey K, Finelli A, Hamilton
R, Joshua AM, Kulkarni G, Zlotta A and Fleshner N: Understanding
how prostate cancer patients value the current treatment options
for metastatic castration resistant prostate cancer. Urol Oncol.
36:240.e13–240.e20. 2018. View Article : Google Scholar
|
|
54
|
Gupta S, Adhami VM, Subbarayan M,
MacLennan GT, Lewin JS, Hafeli UO, Fu P and Mukhtar H: Suppression
of prostate carcinogenesis by dietary supplementation of celecoxib
in transgenic adenocarcinoma of the mouse prostate model. Cancer
Res. 64:3334–3343. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
James ND, Sydes MR, Mason MD, Clarke NW,
Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM,
et al: Celecoxib plus hormone therapy versus hormone therapy alone
for hormone-sensitive prostate cancer: first results from the
STAMPEDE multiarm, multistage, randomised controlled trial. Lancet
Oncol. 13:549–558. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Algotar AM, Thompson PA, Ranger-Moore J,
Stratton MS, Hsu CH, Ahmann FR, Nagle RB and Stratton SP: Effect of
aspirin, other NSAIDs, and statins on PSA and PSA velocity.
Prostate. 70:883–888. 2010.PubMed/NCBI
|
|
57
|
Derry S, Wiffen PJ, Moore R, McNicol ED,
Bell RF, Carr DB, McIntyre M and Wee B: Oral nonsteroidal
anti-inflammatory drugs (NSAIDs) for cancer pain in adults.
Cochrane Database Syst Rev. 7:CD0126382017.PubMed/NCBI
|
|
58
|
Singer EA, Palapattu GS and Van
Wijngaarden E: Prostate-specific antigen levels in relation to
consumption of nonsteroidal anti-inflammatory drugs and
acetaminophen: Results from the 2001–2002 National Health and
Nutrition Examination Survey. Cancer. 113:2053–2057. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ko CJ, Lan SW, Lu YC, Cheng TS, Lai PF,
Tsai CH, Hsu TW, Lin HY, Shyu HY, Wu SR, et al: Inhibition of
cyclooxygenase-2-mediated matriptase activation contributes to the
suppression of prostate cancer cell motility and metastasis.
Oncogene. 36:4597–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Woo DH, Han IS and Jung G: Mefenamic
acid-induced apoptosis in human liver cancer cell-lines through
caspase-3 pathway. Life Sci. 75:2439–2449. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Penning TM, Steckelbroeck S, Bauman DR,
Miller MW, Jin Y, Peehl DM, Fung KM and Lin HK: Aldo-keto reductase
(AKR) 1C3: Role in prostate disease and the development of specific
inhibitors. Mol Cell Endocrinol. 248:182–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Škarydová L, Živná L, Xiong G, Maser E and
Wsól V: AKR1C3 as a potential target for the inhibitory effect of
dietary flavonoids. Chem Biol Interact. 178:138–144. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bauman DR, Rudnick SI, Szewczuk LM, Jin Y,
Gopishetty S and Penning TM: Development of nonsteroidal
anti-inflammatory drug analogs and steroid carboxylates selective
for human aldo-keto reductase isoforms: Potential antineoplastic
agents that work independently of cyclooxygenase isozymes. Mol
Pharmacol. 67:60–68. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Soriano-Hernández AD, Madrigal-Pérez D,
Galván-Salazar HR, Martínez-Fierro ML, Valdez-Velazquez LL,
Espinoza-Gómez F, Vazquez-Vuelvas OF, Olmedo-Buenrostro BA,
Guzman-Esquivel J, Rodriguez-Sanchez IP, et al: Anti-inflammatory
drugs and uterine cervical cancer cells: Antineoplastic effect of
meclofenamic acid. Oncol Lett. 10:2574–2578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gallavan RH Jr and Chou CC: The effects of
mefenamic acid on postprandial intestinal carbohydrate metabolism.
Prostaglandins. 31:1069–1076. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gaertner J, Stamer UM, Remi C, Voltz R,
Bausewein C, Sabatowski R, Wirz S, Müller-Mundt G, Simon ST,
Pralong A, et al: Metamizole/dipyrone for the relief of cancer
pain: A systematic review and evidence-based recommendations for
clinical practice. Palliat Med. 31:26–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chen SS, Cheng TC, Chiu LP, Tasi LY, Huang
SS and Tsay SL: Predictors for lower urinary tract symptoms and the
urinary specific quality of life in prostate cancer patients:
One-year follow-up. J Chinese Med Assoc. 82:482–487. 2019.
View Article : Google Scholar
|
|
68
|
Vagnildhaug OM, Blum D, Wilcock A, Fayers
P, Strasser F, Baracos VE, Hjermstad MJ, Kaasa S, Laird B, Solheim
TS, et al: The applicability of a weight loss grading system in
cancer cachexia: A longitudinal analysis. J Cachexia Sarcopenia
Muscle. 8:789–797. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kelly SP, Graubard BI, Andreotti G, Younes
N, Cleary SD and Cook MB: Prediagnostic body mass index
trajectories in relation to prostate cancer incidence and mortality
in the PLCO cancer screening trial. J Natl Cancer Inst.
109:2016.
|
|
70
|
Cantarutti A, Bonn SE, Adami HO, Grönberg
H, Bellocco R and Bälter K: Body mass index and mortality in men
with prostate cancer. Prostate. 75:1129–1136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Reid J, Hughes CM, Murray LJ, Parsons C
and Cantwell MM: Non-steroidal anti-inflammatory drugs for the
treatment of cancer cachexia: A systematic review. Palliat Med.
7:295–303. 2013. View Article : Google Scholar
|
|
72
|
Kobayashi S, Okada S, Yoshida H and
Fujimura S: Indomethacin Enhances the Cytotoxicity of VCR and ADR
in human pulmonary adenocarcinoma cells. Tohoku J Exp Med.
181:361–370. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kim JK, Jeong CW, Ku JH, Kim HH and Kwak
C: Prostate specific antigen (PSA) persistence 6 weeks after
radical prostatectomy and pelvic lymph node dissection as
predictive factor of radiographic progression in node-positive
prostate cancer patients. J Cancer. 10:2237–2242. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kanzaki H, Kataoka M, Nishikawa A, Uwatsu
K, Nagasaki K, Nishijima N and Hashine K: Kinetics differences
between PSA bounce and biochemical failure in patients treated with
125I prostate brachytherapy. Jpn J Clin Oncol. 45:688–694. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Fenner A: Prostate cancer: PSA kinetics
predict survival in patients treated with abiraterone. Nat Rev
Urol. 12:2402015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Takeuchi H, Ohori M and Tachibana M:
Clinical significance of the prostate-specific antigen doubling
time prior to and following radical prostatectomy to predict the
outcome of prostate cancer. Mol Clin Oncol. 6:249–254. 2017.
View Article : Google Scholar : PubMed/NCBI
|
